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Summary
Objectives: Patients with knee osteoarthritis (OA) often suffer pain that is not fully controlled by analgesics and often require intra-articular
therapies. The aim of this study was to compare the beneﬁts of intra-articular corticosteroid injections (CSIs) and tidal irrigation (TI) in patients
with OA of the knee.
Methods: We performed a dual-centre, single blind, randomised, parallel group trial comparing TI and CSI. Patients with knee OA were rand-
omised to either irrigation using a 3.2 mm arthroscope under local anaesthesia or an intra-articular injection of 40 mg triamcinolone acetonide
and 1% lidocaine. Patients were followed for 6 months. The primary outcome measure was the Western Ontario and McMaster Universities
OA Index total pain score (visual analogue scale, VAS).
Results: One hundred and ﬁfty patients were recruited of whom 71 received TI and 79 CSI. In both treatment groups, over 80% of patients
reported improvement at 2 and 4 weeks. After this time, the beneﬁt of CSI decreased whereas that of TI was maintained: at 26 weeks the pain
relief afforded by TI was signiﬁcantly greater than that of CSI. At 26 weeks 29% of the CSI group reported improvement vs 64% of the TI group
(P< 0.001). Patients with a knee effusion responded better to both treatments, however, this was most apparent for CSI. Patients with less
severe radiographic OA also obtained the greatest improvement from both treatments.
Conclusion: Both procedures lead to signiﬁcant short-term pain relief of at least 4 weeks, however, TI displayed a signiﬁcantly greater duration
of beneﬁt. Patients with effusions and milder radiographic change obtained the best response to treatment.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) of the knee is a common cause of pain
and disability in the middle aged and elderly. Most currently
available therapies for the treatment of OA aim to reduce
pain and increase function, but have little effect on reducing
the progression of the underlying disease. The most com-
monly used treatments are paracetamol, oral non-steroidal
anti-inﬂammatory drugs (NSAIDs) and Cox-2 inhibitors.
These drugs, although certainly effective in reducing pain
and improving function1, rarely lead to complete pain relief
and can be associated with considerable side effects.1This research was supported by an NHS Executive Project
Grant.
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733Intra-articular corticosteroids injections (CSIs) are often
employed to treat pain in OA especially in the presence
of an effusion. There is good evidence that these injections
lead to substantial pain relief, however, their beneﬁt may be
limited to several weeks, although some patients do obtain
beneﬁt lasting for several months.
Several studies have examined the effectiveness of
lavage and tidal irrigation (TI) of the knee in patients with
knee OA. There is evidence that TI: is better than usual
medical care2, leads to a more sustained improvement
than intra-articular CSIs3, has similar results to arthroscopic
washout4 but with discrepant results when compared with
sham procedures5,6. The pain relief following TI is attributed
to the removal of intra-articular debris and inﬂammatory me-
diators from the joint space. ‘‘Wear particles’’, which are of-
ten found in the synovial ﬂuid of joints with OA, have been
shown to induce inﬂammatory mediators and also induce
an OA like arthropathy when injected into the joints of ani-
mals7e9. By removing wear particles, TI may therefore pro-
duce more sustained reductions in inﬂammation and pain
when compared to CSI. The aim of this study was to
734 N. K. Arden et al.: Irrigation vs steroid injection in knee OAcompare the degree and duration of pain relief afforded by
CSI and TI in the management of patients with knee OA.MethodsSTUDY DESIGNThe KIVIS Study is a dual-centre, single blind, blind observer, rando-
mised, parallel group trial comparing TI and CSIs. The ethics committees
at each centre approved the protocol.PATIENTSEligible patients attending routine rheumatology and orthopaedic clinics at
the two participating hospitals were informed about the study by their clini-
cian who passed their details to the study research nurse who recruited
the patients into the study. Patients were eligible if they: had a clinical diag-
nosis of knee OA, had knee pain for most days of the prior month, had radio-
graphic evidence consistent with knee OA and were between 40 and 90
years of age. Exclusion criteria included: symptomatic hip OA, co-existent
inﬂammatory or crystal arthritis, prior knee surgery, injury to the knee in
the preceding 6 months or any intra-articular injection in the preceding 3
months or inability to provide informed consent.
All patients were assessed at an initial visit by a rheumatologist to conﬁrm
eligibility to enter the study and to obtain informed consent. Patients received
standard antero-posterior weight-bearing and lateral radiographs of both
knees if these had not been performed in the previous 6 months. These ﬁlms
were graded at the end of the trials by two independent rheumatologists
(KMJ and LT) according to the Kellgren and Lawrence (K&L) criteria10.
Where the two readers did not agree, a consensus reading with both readers
present was performed.
After written informed consent had been obtained, patients were rando-
mised, using sealed envelopes, by random number generation, stratiﬁed
by centre to either TI or intra-articular steroid injection. Both procedures
were performed by rheumatologists experienced in the techniques.INTERVENTIONSTable I
Baseline clinical characteristics of the patients
TI (n¼ 71) CSI (n¼ 79)
Age (years) 64.9 (9.7) 67.7 (9.1)
Height (cm) 162.9 (9.8) 165.5 (9.8)
Weight (kg) 83.3 (15.2) 87.2 (13.6)Group 1: TI of the knee. This was done as a day case procedure under
local anaesthetic. The medial patello-femoral approach was used. After full
aseptic preparation, the skin and soft tissues were inﬁltrated with 5e10 ml
of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% ligno-
caine. After an initial puncture using a scalpel, a 3.2 mm diameter wrist ar-
throscope was advanced into the joint cavity. Up to 1 l of 0.9% normal
saline was then irrigated through the joint: saline was run into the joint until
fully distended and then allowed to ﬂow out of the joint in a cyclical method
until the aspirated ﬂuid runs clear for at least three successive cycles.
Group 2: Intra-articular CSI. After full aseptic preparation, 40 mg triamcin-
olone acetonide and 2 ml 1% lignocaine were injected into the joint cavity
using the medial patello-femoral approach via a 21-gauge needle.
Both groups were advised to rest for 48 h post procedure. All patients
were given standard dressings to apply to the wound before each follow-
up visit in order to fully cover the procedure site and maintain the assessor’s
(study nurse) blinding. In addition they were advised not to inform the blinded
assessor of their group allocation in order to maintain blinding. All patients
were free to adjust the dosage or change their medications, both prescribed
and over the counter, throughout the follow-up period and reported their
intake using an analgesic diary for the 2-week period before each clinic visit.Gender (% female) 73.2 58.2
Bilateral knee OA (%) 63.4 60.8FOLLOW-UP
Duration of knee OA
(months)z
60 (24,120) 54 (29,120)
Previous CSI (%)* 32.4 45.6
Pain at rest (%)y 69.0 58.2
Varus deformity (%)* 62.0 64.6
Crepitus (%)y 94.4 92.4
Effusion (%)y 56.3 64.6
Heberden’s nodes 94.4 93.7
K&L grades 0 and 1 (%) 16.9 10.1
K&L grade 2 (%) 67.6 68.4
K&L grades 3 and 4 (%) 11.3 20.3
Chondrocalcinosis (%) 4.2 3.8The patients were assessed at 0, 2, 4, 12 and 26 weeks by a trained
researchnurse,whowasblind to the treatment receivedby the patient, whoad-
ministered the questionnaires and performed a physical examination and per-
formance tests. These assessments included the VAS version of the Western
Ontario andMcMaster UniversitiesOA Index (WOMAC)11 questionnaire, anal-
gesic intake, physical examination for effusions (classiﬁed as present if either
the bulge test or the patellar tap signs were positive, warmth and tenderness),
a 50 m walk time, time to climb 10 stairs and a record of the side effects of the
procedure. At all follow-up visits patients were asked to rate the change in the
symptoms in the treated knee compared to baseline using a ﬁve-point Likert
scale ranging frommuchworse tomuch better. At baseline and 26weeks, sub-
jects completed the hospital anxiety and depression12 questionnaire.Values presented are means (SD) unless stated otherwise.
*Either knee.OUTCOMEyStudy knee.
zMedian (IQR).The primary outcome measure was the total WOMAC pain score at 26
weeks using the VAS (score 0e500) with higher scores indicating morepain. Secondary outcome measures included: WOMAC physical function
score, WOMAC stiffness score, patients self reported improvement, time to
walk 50 m and to climb and descend 10 stairs and analgesic intake.STATISTICSAll outcome measures were treated as last observation called forward
(LOCF) so that data were available for every subject at each time point.
However, the actual numbers of subjects with data were also presented.
Means and standard deviations (SDs) are given for normally distributed
data, and differences between treatment groups were evaluated by regres-
sion techniques. These analyses were performed before and after adjusting
for baseline age, gender, duration of symptoms and radiographic age.
Medians and inter-quartile ranges (IQRs) were presented for non-normally
distributed variables, and differences between treatment groups were inves-
tigated using KruskaleWallis (non-parametric) tests. Predictors of change in
WOMAC pain score (normally distributed) were also explored using regres-
sion techniques. All analyses were performed using Stata version 9.2 (Stata-
corp, TX, USA).SAMPLE SIZETo detect a standardised effect size of 0.6 with 90% power, signiﬁcant at
the 5% level, 65 patients were required in each treatment group. An effect
size of 0.6 is widely accepted as being clinically signiﬁcant and would enable
a difference between groups of 12 mm on a 100 mm VAS WOMAC pain
scale to be detected. Allowing for 20% drop-out/loss to follow-up, a total sam-
ple of around 150 patients was required.
Results
Table I shows clinical data for the 150 patients recruited
into the study. The two treatment groups were well matched
for the most baseline clinical characteristics. Pain at rest was
reported by almost two thirds of patients, average duration of
symptomswas approximately 5 years in the index knee, 62%
reported bilateral symptoms. Clinically detectable effusions
were present in 61% of patients and Heberden’s nodes
were detected in 94% of patients. Thirty nine percent of
patients had previously received CSIs for their symptoms
but none had received TI. Questionnaires were completed
at the 26-week visit by 136 patients (90.6%) with six drop-


















Number completed visit = 77
Lost to follow up  = 1
DNA = 1
Number completed visit = 69
Lost to follow up = 1
Number completed visit = 77
Lost to follow up = 1
Number completed visit = 68
Lost to follow up = 1
Number completed visit = 73
Lost to follow up = 4
Number completed visit = 65
Lost to follow up = 3
Number completed visit = 70
Lost to follow up = 1
Number completed visit = 71
Lost to follow up = 2
Fig. 1. Consort diagram (study ﬂow diagram).
735Osteoarthritis and Cartilage Vol. 16, No. 6EFFECTIVENESS OF INTERVENTIONSBoth interventions lead to a substantial reduction in the
WOMAC pain score of approximately 40% at 2 weeks
post injection (Fig. 2). At this time point just over 80% of pa-
tients in each group felt that their knee pain had improved
compared to baseline (Fig. 3). From 4 weeks to the end
of the study both the mean change in the WOMAC pain
score and the number of patients reporting an improvement
decreased signiﬁcantly in the CSI group such that by 26
weeks the mean reduction in WOMAC pain was 7.7%
with only 29% of patients reporting an improvement. Con-
versely, the improvement in the TI group was maintained
out to 26 weeks with a 29.5% reduction in WOMAC pain
and with 64% of patients still reporting an improvement in
their symptoms. At 12 and 26 weeks, the improvement in
WOMAC pain score and the number of subjects reporting
an improvement in symptoms was signiﬁcantly greater in
the TI group compared to the CSI group (Table II, Fig. 3).
These results were essentially unchanged after adjustingfor baseline age, gender, disease duration and radiographic
grade, except that the differences at 12 weeks became non-
signiﬁcant.
Similar improvements, with statistically signiﬁcant be-
tween group differences in favour of TI at 12 and 26 weeks
(Table II), were noted for the secondary outcome measures
including WOMAC function and stiffness scores. Improve-
ment was noted in both the 50 m walk time and the time
to climb 10 stairs, however, there were no statistically signif-
icant differences between the two treatment groups at 12
and 26 weeks. Analgesic/NSAID intake did not differ be-
tween the two groups at any time point.PREDICTORS OF RESPONSEWe examined the dataset for clinical predictors of re-
sponse to CSI or TI. There was a trend for both treatments
to produce a greater improvement in WOMAC pain scores
at 26 weeks in patients with a clinically detectable effusion




































* p < 0.05
** p < 0.01
Fig. 2. WOMAC total pain score (median and IQRs).
736 N. K. Arden et al.: Irrigation vs steroid injection in knee OApresence of an effusion on pain relief was most marked for
patients who received a CSI (difference in change in pain at
26 weeks: 47.5, 95% CI [conﬁdence interval] 2.2, 92.9 for
presence vs absence of effusion): in patients with no effu-
sion, the mean WOMAC score actually deteriorated over
the 6 month follow-up period (Fig. 4). The effect of effusions
was present, but not statistically signiﬁcant, in patients who
received TI, consequently the additional beneﬁt on pain re-
duction of TI over CSI was greater in those patients with no
clinically detectable effusion 76.5 (95% CI 21.7,131.2;
P< 0.007) compared to those with an effusion 46.0 (95%
CI 1.39, 90.5; P¼ 0.043). These differences were less
marked at 2 and 4 weeks: 4 weeks e no clinically detect-
able effusion 30.2 (95% CI 7.0, 67.4; NS) compared to
those with an effusion 16.9 (95% CI 24.5, 58.4, NS).
Increasing radiographic severity was associated with less
pain relief for both treatment groups (P< 0.05 combined).
This loss of pain relief with more severe radiographic
change was most marked in the CSI group where the im-
provements in the WOMAC pain score were not statistically
greater than zero for both K&L grade 2 (14.2, 95% CI
12.3, 40.7; P¼ 0.19) and grades 3 and 4 combined
(1.9, 95% CI 39.0, 35.2; P> 0.5). In the TI group signif-
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Fig. 3. Patient self reported improvement.(80.4, 95% CI 46.9, 113.9; P< 0.01) with a more moderate
response for grades 3 and 4 combined (36.2, 95% CI
20.4, 93.6; P¼ 0.17).
When asked before randomisation, 85 patients expressed
a preference for TI, 19 for CSI and 46 expressed no prefer-
ence. Overall, patients who expressed no preference had
greater improvements in pain than that those expressing
a preference for either TI or CSI (P¼ 0.009). There was no
signiﬁcant association between treatment preference and
treatment allocation (P¼ 0.35) and the results presented
above comparing TI vs CSI on pain relief were not signiﬁ-
cantly altered after adjustment for patient preference in
a multivariate model. None of the other variables measured
at baseline predicted outcome to treatment.
Side effects were uncommon; there were no cases of sep-
tic arthritis, wound infections or of ﬁstulae after either proce-
dure. At 2 weeks, increased swelling of the index knee was
noted in eight patients and four from each treatment group.Discussion
We have demonstrated that in patients with knee OA,
CSIs provide short-term pain relief and that TI provides
equivalent short-term relief but with the beneﬁt maintained
to 6 months in the majority of patients. We have also con-
ﬁrmed that the presence of an effusion and a lesser radio-
graphic severity of knee OA are predictors of a good
response to treatment with CSIs.
Intra-articular CSIs are widely used to treat patients with
painful knee OA and their use is advocated in international
guidelines1,13. They have previously been shown to afford
substantial short-term pain relief of up to 8 weeks, with
some authors suggesting more prolonged beneﬁt14. We
have conﬁrmed that 80% of patients report improvement
at 2 and 4 weeks, but also that 29% maintain this improve-
ment out to 6 months. In clinical practice, it would be useful
to identify those patients who maintain their response, how-
ever, previous studies have failed to ﬁnd any consistent
predictive variables, although many had limited statistical
power to detect all but very large differences in effect
between predictive factors15e19. Our data support current
clinical recommendations1 and one previous study16, which
suggest that intra-articular CSIs are most beneﬁcial in pa-
tients with evidence of an effusion. The use of intra-articular
CSIs in patients without an effusion is not precluded by
these results as they still achieved substantial pain relief
at 2 and 4 weeks, which was not signiﬁcantly different to
patients with an effusion. This suggests that the presence
of an effusion is a predictor of durability of response rather
than of response itself. We have demonstrated, for the ﬁrst
time to our knowledge, that patients with milder changes of
OA on radiographs respond signiﬁcantly better to CSIs that
those with more severe changes characterised by substan-
tial joint space loss at 26 weeks. These two predictors may
help in clinical practice in deciding which patients will have
the most durable response to CSIs.
In this group of patients, TI lead to sustained pain relief of
at least 6 months in 64% of patients, being statistically
superior to CSI at 12 and 26 weeks. On adjusting the data
for potential clinical differences at randomisation, including
age, gender, duration of symptoms and radiographic grade,
the results at 26 weeks were essentially unchanged. The
results at 12 weeks still demonstrated a trend towards supe-
riority of TI, however, these differences failed to reach statis-
tical signiﬁcance. This is consistent with a previous study,
which demonstrated that TI had statistically signiﬁcant
Table II
Clinical and functional outcomes according to treatment group
Weeks













71 79 70 77 69 77 68 73 65 71
Continuous outcomes Decrease from baseline
WOMAC total pain
score
254 (88) 247 (97) 98 (86) 79 (80) 103 (87) 82 (90) 79 (106) 44 (96)* 75 (114) 19 (99)**
WOMAC total function
score
853 (312.6) 831 (340.7) 268 (296) 259 (254) 282 (301) 262 (292) 255 (333) 149 (297)* 219 (356) 69 (329)**
WOMAC total stiffness
score
123 (38) 112 (44) 45 (46) 40 (43) 47 (45) 37 (48) 43 (51) 23 (49)* 34 (58) 10 (49)**
50 m walk* (sec):
median (IQR)
50 (45,61) 50 (45,61) 4 (0,8) 3 (1,8) 4 (1,8) 1 (4,7) 2 (2,7) 0 (5,5) 2 (3,8) 0 (5,5)
Time taken to climb 10
stairs (sec): median
(IQR)
9 (7,12) 9 (7,13) 1 (0,2) 1 (0,2) 1 (0,2) 1 (0,3) 1 (1,2) 0 (1,2) 1 (1,2) 0 (1,2)
HAD depression:
median (IQR)
5 (3,7) 3 (5,7) 0 (1,2) 0 (1,1)
HAD anxiety:
median (IQR)
6 (4,9) 6.5 (3.3,11) 1 (1,3) 0 (2,2)*
Mean no. of
analgesics/weeky
28 (14,61) 42 (16,84) 0 (4,5) 1 (0,18) 1 (1,15) 2 (0,24) 0 (2,11) 0 (10,11) 0 (11,13) 0 (14,11)
*P< 0.05, **P< 0.01 and ***P< 0.001 for washout vs steroid injection comparison in an unadjusted regression model. Values are mean and SD unless otherwise stated.
*N¼ 67 and N¼ 69 for washout and steroid injection, respectively.
yMean number of analgesics or NSAIDs taken per week in the ‘‘2 weeks’’ before each visit.
** ***
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Fig. 4. Predictors of response. (a) Change in WOMAC pain score
by radiographic grade and treatment (mean and SE). (b) Change
in WOMAC pain score by effusion and treatment (mean and SE).
738 N. K. Arden et al.: Irrigation vs steroid injection in knee OAimprovements in pain at 6 months, with no signiﬁcant im-
provement for CSI, however, due to its smaller size, it did
not demonstrate a signiﬁcant difference between the two
groups at 6 months3. The procedure is simple and safe to
perform with nomore side effects than CSI. How does TI pro-
duce a more prolonged improvement in pain compare to
CSI? It is well known that joints affected by OA contain par-
ticulate debris including ‘‘wear particles’’, cartilage fragments
and calcium crystals which may trigger an inﬂammatory re-
sponse of the synovial membrane20. Removal of this partic-
ulate debris along with associated cytokines and enzymes
can lead to sustained relief of symptoms. Intra-articular ste-
roid injections, on the contrary, work by attenuating this in-
ﬂammatory response, however, due to their limited half life
and the fact that the debris is not removed form the joint,
symptoms return after a number of weeks in most cases.
One potential limitation of our study is that due to the
ethical and practical problems of performing sham TI, it
was only single blind, which may have lead to a bias in
favour of TI if patients felt that it was a superior treatment.
Our results show that the two procedures lead to similar
improvements in pain initially and only diverged with time.
None of the patients were made aware of the potential dif-
ferences in duration of beneﬁt of the two procedures and
we feel it unlikely therefore, that all of these differences
could be due to a placebo effect.
Furthermore, the patient’s preference for treatment, which
may drive the placebo effects of an intervention, did not differ
between groups and did not affect the results of the study.A double blind, ‘‘sham’’ controlled study of TI has been
performed and found no beneﬁt of TI at any time point
over a 12 month follow-up period, which contradicts the
results of our study6. There are, however, important differ-
ences in the study designs, which may explain these appar-
ently discrepant results. The method of performing TI varied
between the two studies: the most important being the size
of the cannula used. After extensive consultation with rheu-
matologists and orthopaedic surgeons, we used a 3.2 mm
diameter wrist arthroscope, which was felt to be the mini-
mum acceptable diameter to allow the removal of the in-
tra-articular debris usually encountered during arthroscopy
of osteoarthritic knees. The Bradley study used a 14-gauge
cannula, which has a diameter of 2.1 mm, which may have
been too small for the removal of some macroscopic carti-
lage fragments20. Pain reduction at 3 months, measured us-
ing the WOMAC, was 17% as opposed to 31% in our study
and other studies, which raises the possibility that the can-
nula used in their study may have resulted in a sub-optimal
response. This factor may also explain why that study failed
to identify the clinical predictors of response to TI seen in
our study. The failure to show beneﬁt from TI when com-
pared to ‘‘sham’’ may also, in part, be explained by the
‘‘sham’’ procedure involving the injection of 20 ml of
0.25% bupivacaine, which was left in situ, after aspiration
of the knee. Data from previous a small study of patients
with knee OA suggests that intra-articular bupivacaine has
prolonged beneﬁt over and above a placebo injection which
persists well beyond that expected due to its half life21.
A further potential explanation is that the characteristics of
the patients recruited into the two studies differed signiﬁcantly;
our study recruited a greater proportion of patientswithmoder-
ate severity radiographic changes, the group which demon-
strated the greatest beneﬁt of TI over CSI in our study.
In conclusion, CSI and TI both lead to substantial short-
term pain relief in patients with knee OA and are well toler-
ated with few side effects. The beneﬁts of CSI are most
sustained in patients with milder radiographic OA and those
with a clinically detectable effusion. The beneﬁts of TI are
more sustained that CSI, with the greatest additional beneﬁt
over and above CSI, seen in patients without a detectable
knee effusion and with more severe radiographic change.
The beneﬁts of TI need to be balanced against the
increased time and resources required for this procedure.Conﬂict of interest
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